Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iloperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms REPRIEVE
  • Sponsors Novartis; Vanda Pharmaceuticals

Most Recent Events

  • 05 Jul 2016 Results evaluating the safety and effectiveness of iloperidone for the prevention of relapse in schizophrenia published in the CNS Drugs
  • 26 May 2016 Primary endpoint (To determine the efficacy of flexible dosing of iloperidone compared with placebo in relapse prevention with evaluation of patients by psychiatric rating scales.) has been met, as reported in a Vanda Pharmaceuticals media release.
  • 26 May 2016 Status changed from active, no longer recruiting to discontinued as according to a Vanda Pharmaceuticals media release, in a predefined interim analysis conducted after 68 impending relapse events, confirmed the hypothesis that Fanapt was more effective than placebo in relapse preventions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top